EP1589961A4 - Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2 - Google Patents

Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Info

Publication number
EP1589961A4
EP1589961A4 EP04706521A EP04706521A EP1589961A4 EP 1589961 A4 EP1589961 A4 EP 1589961A4 EP 04706521 A EP04706521 A EP 04706521A EP 04706521 A EP04706521 A EP 04706521A EP 1589961 A4 EP1589961 A4 EP 1589961A4
Authority
EP
European Patent Office
Prior art keywords
hiv
treatment
therapeutic composition
therapeutic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04706521A
Other languages
German (de)
English (en)
Other versions
EP1589961A2 (fr
Inventor
Jelen Boguslaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXCYTON-EXCYMER GmbH
EXCYTON EXCYMER GmbH
Original Assignee
EXCYTON-EXCYMER GmbH
EXCYTON EXCYMER GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/353,483 external-priority patent/US20030203045A1/en
Application filed by EXCYTON-EXCYMER GmbH, EXCYTON EXCYMER GmbH filed Critical EXCYTON-EXCYMER GmbH
Publication of EP1589961A2 publication Critical patent/EP1589961A2/fr
Publication of EP1589961A4 publication Critical patent/EP1589961A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP04706521A 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2 Withdrawn EP1589961A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/353,483 US20030203045A1 (en) 2002-04-30 2003-01-29 Therapeutic composition for the treatment of HIV-1 and HIV-2
US353483 2003-01-29
PCT/US2004/002536 WO2004066954A2 (fr) 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Publications (2)

Publication Number Publication Date
EP1589961A2 EP1589961A2 (fr) 2005-11-02
EP1589961A4 true EP1589961A4 (fr) 2006-02-15

Family

ID=32823743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04706521A Withdrawn EP1589961A4 (fr) 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Country Status (9)

Country Link
EP (1) EP1589961A4 (fr)
JP (1) JP2006516633A (fr)
KR (1) KR20050094461A (fr)
CN (1) CN1747726A (fr)
AU (1) AU2004206996A1 (fr)
CA (1) CA2514252A1 (fr)
RU (1) RU2005123957A (fr)
WO (1) WO2004066954A2 (fr)
ZA (1) ZA200505977B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101810625B (zh) * 2010-04-09 2012-05-23 上海新康制药厂 蒲公英甾醇的应用
JP2021161045A (ja) * 2020-03-31 2021-10-11 株式会社古川リサーチオフィス 亜鉛化合物配合組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001949A1 (fr) * 1988-08-18 1990-03-08 The Australian National University Compositions a base d'inuline gamma
WO1990011761A1 (fr) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Traitement de la demence du sida, de la myelopathie et de la cecite
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
WO1992021368A1 (fr) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition et procede de traitement de maladies
RU2107502C1 (ru) * 1997-03-27 1998-03-27 Открытое акционерное общество "Ветеринарные препараты" Ветеринарный препарат, обладающий широким спектром действия, - йод однохлористый
WO2001000194A2 (fr) * 1999-06-29 2001-01-04 Jacobs Robert H Technique permettant d'optimiser une activite immune dans le traitement de maladies auto-immunes et de maladies immunes chroniques
WO2002080942A1 (fr) * 2001-04-04 2002-10-17 John Carter Composition pharmaceutique contenant du cuivre, de l'acide salicylique, de la vitamine c et du zinc, utile dans le traitement de differentes pathologies telles qu'une infection bacterienne ou virale
RU2195277C2 (ru) * 2001-02-09 2002-12-27 Третьяков Василий Васильевич Способ лечения вич-инфекций
US20030203045A1 (en) * 2002-04-30 2003-10-30 Boguslaw Jelen Therapeutic composition for the treatment of HIV-1 and HIV-2

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
WO1990001949A1 (fr) * 1988-08-18 1990-03-08 The Australian National University Compositions a base d'inuline gamma
WO1990011761A1 (fr) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Traitement de la demence du sida, de la myelopathie et de la cecite
WO1992021368A1 (fr) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition et procede de traitement de maladies
RU2107502C1 (ru) * 1997-03-27 1998-03-27 Открытое акционерное общество "Ветеринарные препараты" Ветеринарный препарат, обладающий широким спектром действия, - йод однохлористый
WO2001000194A2 (fr) * 1999-06-29 2001-01-04 Jacobs Robert H Technique permettant d'optimiser une activite immune dans le traitement de maladies auto-immunes et de maladies immunes chroniques
RU2195277C2 (ru) * 2001-02-09 2002-12-27 Третьяков Василий Васильевич Способ лечения вич-инфекций
WO2002080942A1 (fr) * 2001-04-04 2002-10-17 John Carter Composition pharmaceutique contenant du cuivre, de l'acide salicylique, de la vitamine c et du zinc, utile dans le traitement de differentes pathologies telles qu'une infection bacterienne ou virale
US20030203045A1 (en) * 2002-04-30 2003-10-30 Boguslaw Jelen Therapeutic composition for the treatment of HIV-1 and HIV-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL RESEARCH 1999 NETHERLANDS, vol. 43, no. 2, 1999, pages 123 - 133, ISSN: 0166-3542 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1999, HARAGUCHI Y ET AL: "Inhibition of HIV-1 infection by zinc group metal compounds", XP002358702, Database accession no. EMB-1999309523 *
DATABASE WPI Section Ch Week 199849, Derwent World Patents Index; Class B05, AN 1998-581141, XP002358705 *
DATABASE WPI Section Ch Week 200318, Derwent World Patents Index; Class B05, AN 2003-181626, XP002358706 *
GEORGIOU N A ET AL: "INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REPLICATION IN HUMAN MONONUCLEAR BLOOD CELLS BY THE IRON CHELATORS DEFEROXAMINE, DEFERIPRONE AND BLEOMYCIN", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 181, no. 2, February 2000 (2000-02-01), pages 484 - 490, XP001027530, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
RU2005123957A (ru) 2006-01-27
WO2004066954A3 (fr) 2005-03-17
AU2004206996A1 (en) 2004-08-12
KR20050094461A (ko) 2005-09-27
CA2514252A1 (fr) 2004-08-12
CN1747726A (zh) 2006-03-15
ZA200505977B (en) 2006-05-31
EP1589961A2 (fr) 2005-11-02
WO2004066954A2 (fr) 2004-08-12
JP2006516633A (ja) 2006-07-06

Similar Documents

Publication Publication Date Title
EP1495141A4 (fr) Therapeutique du vih
IL183537A0 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
AP1908A (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
GB0201674D0 (en) Medical treatment
HK1078784A1 (en) Therapeutic treatment
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
ZA200500431B (en) Medicinal composition for treating arteriosclerosis
EP1525216A4 (fr) Therapie combinee pour le traitement d'infection vih
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL397023A1 (pl) Środek leczniczy do leczenia AIDS
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1589961A4 (fr) Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2
GB0300078D0 (en) Composition for the treatment of HIV and AIDS
GB0212790D0 (en) Medicament for the treatment of diabetes
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOGUSLAW, JELEN

A4 Supplementary search report drawn up and despatched

Effective date: 20060102

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070313